Collectively, our observations in primary breast tumors and in breast cancer cells in vitro provide evidence that the overexpression of 14-3-3ζ and the associated 14-3-3ζ gene signature identify a subgroup of ER-positive tumors most likely to be resistant to endocrine therapies and to show early recurrence. The gene discussed is ESR1; the disease is breast cancer.